- Anaesthesia
- Anatomy
- Biochemistry
- Cardiac Surgery
- Cardiology
- Dentistry
- Dermatology
- Emergency Medicine
- Endocrinology
- Forensic Medicine
- Gastroenterology
- General Medicine
- General Surgery
- Genetics
- Geriatrics Medicine
- Health & Nursing
- Hematology
- Histology
- Hospital Administration
- Hospital Management
- Medical Education
- Medicine
- Microbiology
- Nephrology
- Neuro Surgery
- Neurology
- Neuroscience
- Nursing
- Obstetrics & Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Otolaryngology
- Pathology
- Pediatrics
- Pediatrics Surgery
- Pharmacology
- Physiology
- Physiotherapy
- Plastic Surgery
- Preventive And Social Medicine
- Psychiatry
- Radiology
- Respiratory Medicine
- Rheumatology
- Sports Medicine
- Surgery
- Transfusion Medicine
- Urology
Pharmacology
HEALTH TECHNOLOGY ASSESSMENTS AND RARE DISEASES - VOLUME 13 PHARMACEUTICALS POLICY AND LAW
ISBN : 9781607509820
Share Link:
Title of the books is HEALTH TECHNOLOGY ASSESSMENTS AND RARE DISEASES - VOLUME 13 PHARMACEUTICALS POLICY AND LAW. Author Name :J.L. VALVERDE AND J. PREVOT. Excellent book for the MBBS, 3 Year. Published by IOS PRESS. Rare diseases affect between 6 and 8% of the total EU population - around 30 million Europeans. The limited number of patients affected by any one rare disease and the consequent fragmentation of knowledge, means that working at a European level is not only beneficial, it is also essential. Health Technology Assessments (HTAs) and similar assessment procedures are increasingly being used to measure the efficacy and cost effectiveness of health technologies.
Add to Cart
Buy Now
Delivery Charges Applicable
- Satisfaction 100% Guaranteed
- Shipping Charges Applicable
- Latest Editions
Title of the books is HEALTH TECHNOLOGY ASSESSMENTS AND RARE DISEASES - VOLUME 13 PHARMACEUTICALS POLICY AND LAW. Author Name :J.L. VALVERDE AND J. PREVOT. Excellent book for the MBBS, 3 Year. Published by IOS PRESS. Rare diseases affect between 6 and 8% of the total EU population - around 30 million Europeans. The limited number of patients affected by any one rare disease and the consequent fragmentation of knowledge, means that working at a European level is not only beneficial, it is also essential. Health Technology Assessments (HTAs) and similar assessment procedures are increasingly being used to measure the efficacy and cost effectiveness of health technologies.
Specifications
| Author | J.L. VALVERDE AND J. PREVOT |
| Edition | CURRENT EDITION |
| Year | 2011 |
| Publisher | IOS PRESS |
| Binding | PAPERBACK |
Product Reviews
There are no reviews yet.
Write Review